LANTERN PHARMA INC (LTRN) Stock Price, Quote, News and Overview
NASDAQ:LTRN - Nasdaq - US51654W1018 - Common Stock - Currency: USD
LTRN Quote, Performance and Key Statistics
NASDAQ:LTRN (3/6/2025, 8:00:01 PM)
3.89
0 (0%)
The current stock price of LTRN is 3.89 USD. In the past month the price decreased by -24.32%. In the past year, price decreased by -52.96%.
LTRN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.83 | 372.42B | ||
| AMGN | AMGEN INC | 16.04 | 170.67B | ||
| GILD | GILEAD SCIENCES INC | 25.17 | 144.59B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1674.9 | 124.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.3 | 76.35B | ||
| ARGX | ARGENX SE - ADR | 238.59 | 37.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.00B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.57B | ||
| BIIB | BIOGEN INC | 8.95 | 21.47B | ||
| NTRA | NATERA INC | N/A | 18.68B | ||
| GMAB | GENMAB A/S -SP ADR | 24.96 | 15.06B |
Related stock screener links
About LTRN
Company Profile
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 21 full-time employees. The company went IPO on 2020-06-11. The firm is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Company Info
LANTERN PHARMA INC
1920 Mckinney Avenue, 7th Floor
Dallas TEXAS 75201 US
CEO: Panna Sharma
Employees: 21
Company Website: https://www.lanternpharma.com/
Investor Relations: http://ir.lanternpharma.com
Phone: 19722771136
LANTERN PHARMA INC / LTRN FAQ
What is the stock price of LANTERN PHARMA INC today?
The current stock price of LTRN is 3.89 USD.
What is the ticker symbol for LANTERN PHARMA INC stock?
The exchange symbol of LANTERN PHARMA INC is LTRN and it is listed on the Nasdaq exchange.
On which exchange is LTRN stock listed?
LTRN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LANTERN PHARMA INC stock?
7 analysts have analysed LTRN and the average price target is 22.44 USD. This implies a price increase of 476.86% is expected in the next year compared to the current price of 3.89. Check the LANTERN PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LANTERN PHARMA INC worth?
LANTERN PHARMA INC (LTRN) has a market capitalization of 41.93M USD. This makes LTRN a Nano Cap stock.
How many employees does LANTERN PHARMA INC have?
LANTERN PHARMA INC (LTRN) currently has 21 employees.
What are the support and resistance levels for LANTERN PHARMA INC (LTRN) stock?
LANTERN PHARMA INC (LTRN) has a support level at 3.88 and a resistance level at 4.68. Check the full technical report for a detailed analysis of LTRN support and resistance levels.
Should I buy LANTERN PHARMA INC (LTRN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LTRN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LTRN, evaluating the profitability, health, valuation and growth aspects
- LANTERN PHARMA INC (LTRN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LANTERN PHARMA INC (LTRN) Sales and EPS estimates to see what analysts future expectations are.
- LANTERN PHARMA INC (LTRN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LANTERN PHARMA INC (LTRN) Insider and Institutional Ownership to learn about the owners and their transactions.
- LANTERN PHARMA INC (LTRN) Stock Chart to make your own analysis
- LANTERN PHARMA INC (LTRN) Latest news and press-releases to stay up to date.
Does LANTERN PHARMA INC (LTRN) stock pay dividends?
LTRN does not pay a dividend.
When does LANTERN PHARMA INC (LTRN) report earnings?
LANTERN PHARMA INC (LTRN) will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of LANTERN PHARMA INC (LTRN)?
LANTERN PHARMA INC (LTRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.78).
What is the Short Interest ratio of LANTERN PHARMA INC (LTRN) stock?
The outstanding short interest for LANTERN PHARMA INC (LTRN) is 2.41% of its float. Check the ownership tab for more information on the LTRN short interest.
LTRN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to LTRN. When comparing the yearly performance of all stocks, LTRN is a bad performer in the overall market: 85.9% of all stocks are doing better.
LTRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LTRN. LTRN has a great financial health rating, but its profitability evaluates not so good.
LTRN Financial Highlights
Over the last trailing twelve months LTRN reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS decreased by -27.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.02% | ||
| ROE | -71.78% | ||
| Debt/Equity | 0 |
LTRN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to LTRN. The Buy consensus is the average rating of analysts ratings from 7 analysts.